Search
Search Results
-
Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
Given the rarity of RAD51C mutations, the risk and treatment of metachronous breast cancer after the diagnosis of ovarian cancer in RAD51C mutation...
-
Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
BackgroundInhibitors of
P oly (A DP-R ibose)P olymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising...
-
Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
BackgroundShort-term starvation (STS) has gradually been confirmed as a treatment method that synergistically enhances the effect of chemotherapy on...
-
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
BackgroundImmune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that...
-
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
BackgroundPrevious clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients...
-
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
BackgroundDespite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical...
-
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
BackgroundManagement of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in...
-
Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
ObjectiveTo analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer...
-
Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Poly (ADP-ribose) Polymerase-1 (PARP-1) is a member of 17 membered PARP family having diversified biological functions such as synthetic lethality,...
-
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
Over the last few decades, the incidence of urogenital cancers has exhibited diverse trends influenced by screening programs and geographical...
-
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
BackgroundPoly(ADP-ribose) polymerase inhibitors (PARPis) specifically target homologous recombination deficiency (HRD) cells and display good...
-
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
BackgroundPARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which...
-
Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models
PurposeTo develop physiologically based finite time pharmacokinetic (PBFTPK) models for the analysis of oral pharmacokinetic data.
Methods ...
-
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
BackgroundPoly-ADP ribose polymerase (PARP) inhibitor-based cancer therapy selectively targets cells with deficient homologous recombination repair....
-
PARP inhibitors: enhancing efficacy through rational combinations
Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment landscape for tumours harbouring defects in genes involved...
-
Functional annotation of variants of the BRCA2 gene via locally haploid human pluripotent stem cells
Mutations in the BRCA2 gene are associated with sporadic and familial cancer, cause genomic instability and sensitize cancer cells to inhibition by...
-
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer
BackgroundPoly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) are becoming the standard of care for epithelial ovarian cancer...
-
Novel insights into DNA damage repair defects in HPV-positive head and neck squamous cell carcinoma: from the molecular basis to therapeutic opportunities
The incidence of human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCC) has dramatically increased in recent decades....
-
Genomics in ‘Personalised’ Management of Breast Carcinoma
Breast cancer is a disease caused by a host of factors which also include accumulation of genetic aberrations over a period of time. Most breast...